SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

by Jackeline Agorreta, Ana Remirez, Ruben Pio, Luis M Montuenga, Teresa Lozano, Esther Redin, Irati Garmendia, Diego Serrano, Yaiza Senent, Miriam Redrado, Maria Villalba, Francisco Exposito, Daniel Ajona, Sergio Ortiz-Espinosa, Cristina Bertolo, Cristina Sainz, Juana Garcia-Pedrero, Juan Lasarte, Alfonso Calvo
Published 2021-03-01